Search
forLearn
5 / 801 resultslearn TDM-105795
learn sh-Polypeptide-7
learn Gamma linolenic acid
learn L-Proline
Research
5 / 1000+ results
research A role for p75 neurotrophin receptor in the control of apoptosis‐driven hair follicle regression
The p75 neurotrophin receptor is important for hair follicle regression by controlling cell death.
research [Construction and identification of mouse model with conditional knockout of p75 neurotrophin receptor gene in epidermal cells by Cre-loxP system].
Removing the p75 gene in mouse skin cells didn't affect their skin or hair growth.
research Hair growth inhibition by psychoemotional stress: a mouse model for neural mechanisms in hair growth control
Stress can stop hair growth in mice, and treatments can reverse this effect.
research HDAC6-dependent deacetylation of NGF dictates its ubiquitination and maintains primordial follicle dormancy
HDAC6 helps keep ovarian follicles dormant, extending female fertility.
research Adaptations in the structure and innervation of follicle‐sinus complexes to an aquatic environment as seen in the Florida manatee (Trichechus manatus latirostris)
Manatee whiskers are specially adapted for touch in water.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community PP405 Update and My Take on Pelage
Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 is NOT gray market jxl069
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.